Physician profile
Daniel S Kassavin
NPI 1144428103
$1,865.64
in general payments reported to CMS, 2019-2025
6 companies · $17.52 in 2025
The $17.52 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $37.67 · 2021: $16.64 · 2022: $12.32 · 2023: $39.44 · 2024: $1,627 · 2025: $17.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,049 · Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,048.99 |
| Food and Beverage | $634.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,623.13 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Inari Medical, INC. | $115.53 | 2019 | |
| Smith+Nephew, INC. | $46.92 | 2022-2025 | Collagenase Santyl, Regranex |
| Boston Scientific Corporation | $32.59 | 2020-2021 | |
| Kerecis Limited | $25.75 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Cardiva Medical, INC. | $21.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kassavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.